Braveheart Bio, Inc. (BRVE) SEC Filings & Earnings Calls
EquiReason read 8 Braveheart Bio, Inc. SEC filings in the last 12 months. Latest: SC 13D/A on 2026-09-10 — OrbiMed entities file amended Schedule 13D disclosing aggregate 13.5% beneficial ownership in Braveheart Bio, with no plans for control or material changes..
Source: SEC EDGAR filings · read by EquiReason
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
8 Sep 202610-QNet loss increased to $29.3M for H1 2026 from $0.5M in H1 2025 as R&D spending commenced for Phase 3 trial.earningsopen
Figures in the filing · each found in the filing text
| Net loss · H1-2026 | $29M | |
| Cash and cash equivalents · Q2-2026 | $123M | +38% y/y |
| Research and development expense · H1-2026 | $22M | |
| Accumulated deficit · Q2-2026 | $96M | +45% y/y |
Risks flagged
Single product candidate dependency
“We are substantially dependent on the success of our only product candidate, BHB-1893, which is a cardiac myosin inhibitor being developed for the treatment of HCM.” · word for word
Reliance on third-party clinical data from China
“We rely on clinical data generated by Hengrui from clinical trials that were not designed or conducted by us, and such data may not be adequate to support our regulatory submissions or future clinical development plans.” · word for word
Need for substantial additional funding
“We will need substantial additional funding. We may be unable to raise capital on acceptable terms, if at all, and, as a result, we may be required to delay, reduce or eliminate our product development or commercialization efforts.” · word for word
8 Sep 20268-K · 2.02Braveheart Bio reports Q2 2026 financial results; cash $122.8M (pre-IPO), net loss $15M; Phase 3 LIONHEART-HCM initiated; IPO completed August 2026 with $439.9M gross proceeds.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q2-2026 | $123M | +38% y/y |
| Research and development expenses · Q2-2026 | $11M | |
| General and administrative expenses · Q2-2026 | $5M | +4700% y/y |
| Net loss · Q2-2026 | $15M | |
| Net loss per share · Q2-2026 | $2.51 |
Risks flagged
No revenue; net loss increasing as clinical programs advance.
“Net loss $15M vs $0.4M prior year; R&D expenses $11.1M vs $0.”
14 Aug 2026SC 13DAndreessen Horowitz (a16z) disclosed an 11.4% activist stake in Braveheart Bio, with a board seat, following a $59.8M investment.open
Figures in the filing · each found in the filing text
| Beneficial Ownership Percentage · 2026-08-07 | 11.4% | |
| Shares Beneficially Owned · 2026-08-07 | 10,232,420 |
Risks flagged
Lock-up Expiration Risk
“each of the Issuer's directors and executive officers, and the holders of substantially all of the Issuer's pre-IPO common stock and securities convertible into or exchangeable for its capital stock, including AH Bio IV, entered into a customary lock-up agreement with the underwriters with respect to its common stock” · word for word
Braveheart Bio, Inc. — questions
- What did Braveheart Bio, Inc. file recently?
- 8 SEC filings in the last 12 months. Latest: SC 13D/A on 2026-09-10 — OrbiMed entities file amended Schedule 13D disclosing aggregate 13.5% beneficial ownership in Braveheart Bio, with no plans for control or material changes.
Every figure on this page comes from Braveheart Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.